This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing recent approval for first biologic treatment of COPD with Dupixent.
Ticker(s): REGNWho's the expert?
- Michael E. Wechsler is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at NJH in Denver
- Director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and Associate Vice President for Innovation and Industry Relations at NJH.
- Professor Wechsler's research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma
pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome, CSS). - Has ledstudies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab.
- He has published more than 250 peer-reviewed manuscripts relating to asthma, GPA and eosinophilic lung diseases.
- Was a member of the Steering Committee and site Principal Investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multicentre asthma clinical trials consortium, and currently serves as the PI of the
Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. - A member of the American Society of Clinical Investigation and the Association of American Physicians, he has participated in many different task forces related to the study
of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society and the International Eosinophil Society. - Currently Associate Editor of the journal Chest and has served as Associate Editor of the journal Allergy and on the editorial board of the European Journal of Clinical Investigation.
Interview GoalThis conversation will focus on the treatment of COPD and the recent approval of the use of Dupixent for patients with COPD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
